Company intelligence / Profile preview

GRI Bio, Inc.

Ownership: Public · GRI
Development stage: Phase 1

Overview

The lead program, GRI‑0621—an oral iNKT cell inhibitor—is in a Phase 2a randomized double-blind study for idiopathic pulmonary fibrosis. Interim biomarker data are expected Q2 2025 and topline results Q3 2025. Additional programs include dNKT agonists for SLE in preclinical development. No efficacy or safety data have been publicly reported as of May 2025.

Therapeutic areas: PulmonologyImmunology
Modalities: Small molecules (NKT cell modulators; oral therapeutics)
Industry: Biotech

Drug pipeline

7 assets

GRI-0621

6 more assets in the full pipeline.

Request access →

Financials

Market cap: $174.3K
Total revenue: $0
Enterprise value: $-10.7M

Beyond the preview

Go deeper on GRI Bio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRI Bio, Inc..

Explore the full profile